AGY:LSE-Allergy Therapeutics plc (GBX)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | LSE

Last Closing Price

GBX 33.50

Change

0.00 (0.00)%

Market Cap

GBX 0.22B

Volume

0.51M

Avg Analyst Target

N/A

Avg User Target

GBX
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-24 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HIK:LSE Hikma Pharmaceuticals PLC

N/A

GBX5.66B 16.72 7.71
INDV:LSE Indivior PLC

N/A

GBX1.68B 17.42 6.88
BXP:LSE Beximco Pharmaceuticals Limite..

N/A

GBX0.85B 13.12 0.13
APH:LSE Alliance Pharma plc

N/A

GBX0.55B 30.91 16.71
AMYT:LSE Amryt Pharma plc

N/A

GBX0.52B N/A 290.92
BMK:LSE Benchmark Holdings plc

N/A

GBX0.42B N/A 22.42
EAH:LSE ECO Animal Health Group plc

N/A

GBX0.19B 23.55 7.88
DNL:LSE Diurnal Group plc

N/A

GBX0.10B N/A N/A
STX:LSE Shield Therapeutics plc

N/A

GBX0.08B 53.33 125.61
MXC:LSE MGC Pharmaceuticals Limited

N/A

GBX0.07B N/A N/A

ETFs Containing AGY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 101.50% 92% A- 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 101.50% 92% A- 96% A
Trailing 12 Months  
Capital Gain 150.47% 100% A+ 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 150.47% 100% A+ 96% A
Trailing 5 Years  
Capital Gain 47.25% 67% D+ 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 47.25% 67% D+ 62% D-
Average Annual (5 Year Horizon)  
Capital Gain 10.11% 31% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.11% 31% F 55% F
Risk Return Profile  
Volatility (Standard Deviation) 57.78% 54% F 26% F
Risk Adjusted Return 17.49% 31% F 37% F
Market Capitalization 0.22B 57% F 43% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 83.75 25% F 9% F
Price/Book Ratio 4.89 43% F 19% F
Price / Cash Flow Ratio 25.60 7% F 20% F
EV/EBITDA 25.16 30% F 24% F
Management Effectiveness  
Return on Equity 6.25% 64% D 45% F
Return on Invested Capital 6.55% 79% C+ 72% C-
Return on Assets 2.82% 64% D 49% F
Debt to Equity Ratio 5.05% 88% B+ 79% C+
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.60 7% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector